Eagle Pharmaceuticals, Inc. (EGRX) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Exhibit 99.1

For Immediate Release

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results

— Bendeka® market share grew to 92% —

— Bendeka reaches $500 million in cumulative sales in Q1 2017, triggering $25 million milestone —

— 2016 Revenue grew 186% to $189.5 million —

— Q4 2016 income before tax benefit grew to $28.3 million, including $15.6 million of accelerated and non-recurring expenses—

— Q4 2016 EPS grew to $3.75 per basic and $3.52 per diluted share —

— Full Year 2016 income before tax benefit grew to $53.4 million —

— Full Year 2016 EPS grew to $5.24 per basic and $4.96 per diluted share —

— Q4 2016 included $29 million of income tax benefit on release of tax valuation allowance —

WOODCLIFF LAKE, N.J.— March 1, 2017—Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2016. Highlights of and subsequent to the fourth quarter of 2016 include:

Business Highlights:

·                 Bendeka total market share rose to 92%, as of February 24, 2017;

·                 Bendeka achieves $500 million in cumulative sales, triggering $25 million sales milestone from Teva in Q1 2017;

·                 Eight new patents allowed by the U.S. Patent and Trademark Office for Eagle’s Bendeka portfolio bringing the total to 14 issued or allowed, with 11 issued to-date and ten listed in the Orange Book;

·                 The Centers for Medicare & Medicaid Services (CMS) established a unique J-Code (J9034) for Bendeka effective January 1, 2017 triggering a $40 million milestone payment from Teva in Q4 2016;

·                 Ryanodex® sales increased to $3.9 million during the fourth quarter;

·                 Completed NDA submission for Ryanodex for Exertional Heat Stroke (EHS) and requested Priority Review;

·                 NDA for Pemetrexed Injection for non-small cell lung cancer and mesothelioma accepted for filing; PDUFA target date of October 30, 2017;

·                 Entered the biologics sector with the acquisition of Arsia Therapeutics, now renamed Eagle Biologics;

·                 Board member, David Pernock, joined Eagle management as President and Chief Commercial Officer; and,